InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Apogee Therapeutics, Inc.

APGE Clue Score7
United States Fiscal year ends December CIK 0001974640
$135.07 +0.00% Close, 4 Sep 2026
Alert on the numbers Alert on insider trades
Price $135.07 +467.52% Close, 4 Sep 2026

Closing prices at the end of each trading day, from 14 Jul 2023. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2022Operating income−30.7Net income−39.8EPS, diluted−16.16Fiscal year 2023Operating income−93.0Net income−84.0EPS, diluted−3.36Fiscal year 2024Operating income−216.9Net income−182.1EPS, diluted−3.30Fiscal year 2025Operating income−285.6Net income−255.8EPS, diluted−4.22
FY2022FY2023FY2024FY2025
Operating income −30.7 −93.0 −216.9 −285.6
Net income −39.8 −84.0 −182.1 −255.8
Growth
EPS, diluted −16.16 −3.36 −3.30 −4.22

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2022Operating cash flow−16.4Fiscal year 2023Operating cash flow−74.8Capital expenditure−0.2Free cash flow−74.9Fiscal year 2024Operating cash flow−171.2Capital expenditure−1.2Free cash flow−172.3Fiscal year 2025Operating cash flow−227.5Capital expenditure−5.1Free cash flow−232.6
FY2022FY2023FY2024FY2025
Operating cash flow −16.4 −74.8 −171.2 −227.5
Capital expenditure n/a −0.2 −1.2 −5.1
Free cash flow n/a −74.9 −172.3 −232.6
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Cash151.9Fiscal year 2023Cash118.3Fiscal year 2024Cash141.8Fiscal year 2025Cash131.5
FY2022FY2023FY2024FY2025
Cash 151.9 118.3 141.8 131.5

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Balance sheet

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023† 31 Dec 2023 FY2024† 31 Dec 2024 FY2025 31 Dec 2025
Assets
151.9 118.3 141.8 131.5
n/a 0.4 2.0 5.7
152.1 401.4 754.0 937.1
Growth +164.0% +87.8% +24.3%
Liabilities
10.0 21.5 37.2 33.3
Equity
−39.8 −123.8 −305.9 −561.8
Per share and net cash
0.0 48.3 58.1 68.4

† The diluted share count jumps at 2023 and 2024, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.